GLPG Stock Overview
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.
Price History & Performance
|Historical stock prices|
|Current Share Price||€52.96|
|52 Week High||€66.28|
|52 Week Low||€41.30|
|1 Month Change||-1.23%|
|3 Month Change||-0.71%|
|1 Year Change||3.36%|
|3 Year Change||-65.45%|
|5 Year Change||-29.88%|
|Change since IPO||231.00%|
Recent News & Updates
|GLPG||NL Biotechs||NL Market|
Return vs Industry: GLPG exceeded the Dutch Biotechs industry which returned -14.1% over the past year.
Return vs Market: GLPG exceeded the Dutch Market which returned -13.4% over the past year.
|GLPG Average Weekly Movement||4.4%|
|Biotechs Industry Average Movement||8.0%|
|Market Average Movement||4.7%|
|10% most volatile stocks in NL Market||7.9%|
|10% least volatile stocks in NL Market||2.9%|
Stable Share Price: GLPG is not significantly more volatile than the rest of Dutch stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: GLPG's weekly volatility (4%) has been stable over the past year.
About the Company
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
Galapagos Fundamentals Summary
|GLPG fundamental statistics|
Is GLPG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GLPG income statement (TTM)|
|Cost of Revenue||€452.74m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 03, 2022
|Earnings per share (EPS)||-1.23|
|Net Profit Margin||-15.96%|
How did GLPG perform over the long term?See historical performance and comparison
Is GLPG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GLPG?
Other financial metrics that can be useful for relative valuation.
|What is GLPG's n/a Ratio?|
Price to Sales Ratio vs Peers
How does GLPG's PS Ratio compare to its peers?
|GLPG PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
PHARM Pharming Group
603087 Gan & Lee Pharmaceuticals
688276 Changchun BCHT Biotechnology
Price-To-Sales vs Peers: GLPG is good value based on its Price-To-Sales Ratio (6.9x) compared to the peer average (23.6x).
Price to Earnings Ratio vs Industry
How does GLPG's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: GLPG is good value based on its Price-To-Sales Ratio (6.9x) compared to the European Biotechs industry average (16.1x)
Price to Sales Ratio vs Fair Ratio
What is GLPG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6.9x|
|Fair PS Ratio||19.6x|
Price-To-Sales vs Fair Ratio: GLPG is good value based on its Price-To-Sales Ratio (6.9x) compared to the estimated Fair Price-To-Sales Ratio (19.6x).
Share Price vs Fair Value
What is the Fair Price of GLPG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GLPG (€52.96) is trading above our estimate of fair value (€3.16)
Significantly Below Fair Value: GLPG is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Galapagos forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GLPG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GLPG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GLPG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GLPG's revenue (5.5% per year) is forecast to grow slower than the Dutch market (7.7% per year).
High Growth Revenue: GLPG's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GLPG is forecast to be unprofitable in 3 years.
Discover growth companies
How has Galapagos performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GLPG is currently unprofitable.
Growing Profit Margin: GLPG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GLPG is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare GLPG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLPG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).
Return on Equity
High ROE: GLPG has a negative Return on Equity (-3.05%), as it is currently unprofitable.
Discover strong past performing companies
How is Galapagos's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GLPG's short term assets (€4.5B) exceed its short term liabilities (€550.7M).
Long Term Liabilities: GLPG's short term assets (€4.5B) exceed its long term liabilities (€1.8B).
Debt to Equity History and Analysis
Debt Level: GLPG is debt free.
Reducing Debt: GLPG has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GLPG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: GLPG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 2.6% each year
Discover healthy companies
What is Galapagos's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GLPG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GLPG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GLPG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GLPG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GLPG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Stoffels (60 yo)
Dr. Paulus A. Stoffels, also known as Paul, Ph D., M.D., is Chief Executive Officer of Galapagos NV since April 01, 2021 and also serves as its Chairman since April 26, 2022 and also serves as Member of Ma...
Experienced Management: GLPG's management team is considered experienced (4.9 years average tenure).
Experienced Board: GLPG's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Galapagos NV's employee growth, exchange listings and data sources
- Name: Galapagos NV
- Ticker: GLPG
- Exchange: ENXTAM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €3.481b
- Shares outstanding: 65.73m
- Website: https://www.glpg.com
Number of Employees
- Galapagos NV
- Generaal De Wittelaan L11 A3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.